Grimes & Company, Inc. Adma Biologics, Inc. Transaction History
Grimes & Company, Inc.
- $3.93 Billion
- Q3 2025
A detailed history of Grimes & Company, Inc. transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 13,674 shares of ADMA stock, worth $212,767. This represents 0.01% of its overall portfolio holdings.
Number of Shares
13,674
Previous 13,674
-0.0%
Holding current value
$212,767
Previous $249,000
19.68%
% of portfolio
0.01%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding ADMA
# of Institutions
402Shares Held
204MCall Options Held
3.06MPut Options Held
1.88M-
Vanguard Group Inc Valley Forge, PA21MShares$326 Million0.0% of portfolio
-
Black Rock Inc. New York, NY18.6MShares$290 Million0.0% of portfolio
-
State Street Corp Boston, MA13.6MShares$211 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA12.5MShares$195 Million0.03% of portfolio
-
Sachem Head Capital Management LP New York, NY8.96MShares$139 Million5.63% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $3.06B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...